1043 Patient-Reported Outcome Measures for Addiction Treatment: Development of a Digital Health Platform using a Patient-Centered Approach Juan-Ignacio Mestre-Pint 1 , Maria Pellicer 1 , Esperanza Vergara 2 , Daniel Folch 1 , Laia Miquel 3 , Carlos Spuch 4 , Adolfo Pin 5 , Julin Mateus 6 , Jess Ruiz 6 , Gustavo Gil-Berrozpe 7 , Francina Fonseca 1 , Elena Garca de Jaln 7 , Fernando Rodrguez de Fonseca 8 , Claudio Tamarit 7 , Francisco Otero 5 , Marta Torrens 1 , Yolanda Pardo 9 1 Hospital del Mar Research Institute, Barcelona, Spain, 2 Universidad de Cdiz, Cdiz, Spain, 3 Hospital Clnic, Barcelona, Spain, 4 Fundacin Pblica Galega de Investigacin Biomdica Galicia Sur, Vigo, Spain, 5 Unidad Asistencial de Drogodependencias CEDRO, Vigo, Spain, 6 Fundacin Hospitalarias, Barcelona, Spain, 7 Instituto de Investigacin Sanitaria de Navarra, Pamplona, Spain, 8 IBIMA Investigacin Biomdica de Mlaga, Mlaga, Spain, 9 Universitat Autnoma de Barcelona, Barcelona, Spain Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :1043 Aims Substance Use Disorders (SUDs) are highly prevalent and impact individuals health, well-being, and social functioning

On its own, glucagon usually raises blood sugar
9 , 10 - Recommendation 2: Efforts should be made to minimize the pulmonary aspiration risk of delayed gastric emptying in the perioperative period
This is due, at least in part, to recent outcome trial data supporting the use of select GLP-1 RAs and SGLT-2 inhibitors to mitigate cardiovascular and renal risks in at-risk patients
Severe but rare side effects can include pancreatitis, medullary thyroid cancer, acute kidney injury, and worsening diabetes related retinopathy
Double knockout animals for both GIPR and GLP-1R (DIRKO) showed in cortical bone the same bone alterations seen in single GLP-1R KO animals [45]